The capsule of Streptococcus equi ssp. zooepidemicus is a target for attenuation in vaccine development

Vaccine

Volumn 30, Issue 31, 2012, Pages 4670-4675

  Wei, Zigong ^a   Fu, Qiang ^a   Chen, Yaosheng ^a   Cong, Peiqing ^a   Xiao, Shuqi ^a   Mo, Delin ^a   He, Zhuyong ^a   Liu, Xiaohong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Capsular; Mutant; Streptococcus equi ssp. zooepidemicus; Vaccine

Indexed keywords

BACTERIAL POLYSACCHARIDE; COMPLEMENT COMPONENT C3; GAMMA INTERFERON; INTERLEUKIN 4; LIVE VACCINE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL; BACTERIAL GENE; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; BACTERIUM MUTANT; CONTROLLED STUDY; FEMALE; HASB GENE; IMMUNIZATION; MACROPHAGE; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; STREPTOCOCCUS EQUI ZOOEPIDEMICUS; STREPTOCOCCUS INFECTION; TRANSMISSION ELECTRON MICROSCOPY; WILD TYPE;

ANIMALS; BACTERIAL CAPSULES; BACTERIAL VACCINES; CELLS, CULTURED; COMPLEMENT C3; FEMALE; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-4; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; PHAGOCYTOSIS; SEQUENCE DELETION; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS EQUI; VACCINES, ATTENUATED; VIRULENCE;

EID: 84861987358     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.092     Document Type: Article

References (29)

1. Waller A.S. Protecting against Streptococcus zooepidemicus opportunism: the challenge of vaccine design. Veterinary Journal 2010, 184(May (2)):128-129.
2. Feng Z.G., Hu J.S. Outbreak of swine streptococcosis in Sichan province and identification of pathogen. Animal Husbandry and Veterinary Medicine Letters 1977, 2:7-12.
3. Hong-Jie F., Fu-Yu T., Ying M., Cheng-Ping L. Virulence and antigenicity of the szp-gene deleted Streptococcus equi ssp. zooepidemicus mutant in mice. Vaccine 2009, 27(January 1 (1)):56-61.
4. Meehan M., Nowlan P., Owen P. Affinity purification and characterization of a fibrinogen-binding protein complex which protects mice against lethal challenge with Streptococcus equi subsp. equi. Microbiology (Reading, England) 1998, 144(April (Pt 4)):993-1003.
5. Causey R.C., Artiushin S.C., Crowley I.F., Weber J.A., Homola A.D., Kelley A., et al. Immunisation of the equine uterus against Streptococcus equi subspecies zooepidemicus using an intranasal attenuated Salmonella vector. Veterinary Journal 2010, 184(May (2)):156-161.
6. Blank L.M., Hugenholtz P., Nielsen L.K. Evolution of the hyaluronic acid synthesis (has) operon in Streptococcus zooepidemicus and other pathogenic streptococci. Journal of Molecular Evolution 2008, 67(July (1)):13-22.
7. Wessels M.R., Moses A.E., Goldberg J.B., DiCesare T.J. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proceedings of the National Academy of Sciences of the United States of America 1991, 88(October 1 (19)):8317-8321.
8. Walker J.A., Timoney J.F. Construction of a stable non-mucoid deletion mutant of the Streptococcus equi Pinnacle vaccine strain. Veterinary Microbiology 2002, 89(November 6 (4)):311-321.
9. Field T.R., Ward P.N., Pedersen L.H., Leigh J.A. The hyaluronic acid capsule of Streptococcus uberis is not required for the development of infection and clinical mastitis. Infection and Immunity 2003, 71(January (1)):132-139.
10. Wibawan I.W., Pasaribu F.H., Utama I.H., Abdulmawjood A., Lammler C. The role of hyaluronic acid capsular material of Streptococcus equi subsp. zooepidemicus in mediating adherence to HeLa cells and in resisting phagocytosis. Research in Veterinary Science 1999, 67(October (2)):131-135.
11. Timoney J.F. The pathogenic equine streptococci. Veterinary Research 2004, 35(July-August (4)):397-409.
12. Levin J.C., Wessels M.R. Identification of csrR/csrS, a genetic locus that regulates hyaluronic acid capsule synthesis in group A Streptococcus. Molecular Microbiology 1998, 30(October (1)):209-219.
13. Graham M.R., Smoot L.M., Migliaccio C.A., Virtaneva K., Sturdevant D.E., Porcella S.F., et al. Virulence control in group A Streptococcus by a two-component gene regulatory system: global expression profiling and in vivo infection modeling. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(October 15 (21)):13855-13860.
14. Biswas I., Gruss A., Ehrlich S.D., Maguin E. High-efficiency gene inactivation and replacement system for gram-positive bacteria. Journal of Bacteriology 1993, 175(June (11)):3628-3635.
15. Hammerschmidt S., Wolff S., Hocke A., Rosseau S., Muller E., Rohde M. Illustration of pneumococcal polysaccharide capsule during adherence and invasion of epithelial cells. Infection and Immunity 2005, 73(August (8)):4653-4667.
16. Thurlow L.R., Thomas V.C., Fleming S.D., Hancock L.E. Enterococcus faecalis capsular polysaccharide serotypes C and D and their contributions to host innate immune evasion. Infection and Immunity 2009, 77(December (12)):5551-5557.
17. Robert Hsueh T.R. Isolation of resting B lymphocytes from one or more groups of four mouse spleens. AfCS Procedure Protocol 2003, PP00000001.
18. Cunnion K.M., Zhang H.M., Frank M.M. Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infection and Immunity 2003, 71(February (2)):656-662.
19. Anzai T., Timoney J.F., Kuwamoto Y., Fujita Y., Wada R., Inoue T. In vivo pathogenicity and resistance to phagocytosis of Streptococcus equi strains with different levels of capsule expression. Veterinary Microbiology 1999, 67(July 1 (4)):277-286.
20. Segura M., Gottschalk M., Olivier M. Encapsulated Streptococcus suis inhibits activation of signaling pathways involved in phagocytosis. Infection and Immunity 2004, 72(September (9)):5322-5330.
21. Smith H.E., Damman M., van der Velde J., Wagenaar F., Wisselink H.J., Stockhofe-Zurwieden N., et al. Identification and characterization of the cps locus of Streptococcus suis serotype 2: the capsule protects against phagocytosis and is an important virulence factor. Infection and Immunity 1999, 67(April (4)):1750-1756.
22. Dale J.B., Washburn R.G., Marques M.B., Wessels M.R. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infection and Immunity 1996, 64(May (5)):1495-1501.
23. Marques M.B., Kasper D.L., Pangburn M.K., Wessels M.R. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infection and Immunity 1992, 60(October (10)):3986-3993.
24. Graveline R., Segura M., Radzioch D., Gottschalk M. TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness. International Immunology 2007, 19(April (4)):375-389.
25. Goldmann O., Rohde M., Chhatwal G.S., Medina E. Role of macrophages in host resistance to group A streptococci. Infection and Immunity 2004, 72(May (5)):2956-2963.
26. Ross G.D., Medof M.E. Membrane complement receptors specific for bound fragments of C3. Advances in Immunology 1985, 37:217-267.
27. Khan A.Q., Chen Q., Wu Z.Q., Paton J.C., Snapper C.M. Both innate immunity and type 1 humoral immunity to Streptococcus pneumoniae are mediated by MyD88 but differ in their relative levels of dependence on toll-like receptor 2. Infection and Immunity 2005, 73(January (1)):298-307.
28. Li Y., Gottschalk M., Esgleas M., Lacouture S., Dubreuil J.D., Willson P., et al. Immunization with recombinant Sao protein confers protection against Streptococcus suis infection. Clinical Vaccine and Immunology 2007, 14(August (8)):937-943.
29. Webb K., Jolley K.A., Mitchell Z., Robinson C., Newton J.R., Maiden M.C., et al. Development of an unambiguous and discriminatory multilocus sequence typing scheme for the Streptococcus zooepidemicus group. Microbiology (Reading, England) 2008, 154(October (Pt 10)):3016-3024.